Copyright
©The Author(s) 2016.
World J Virol. Aug 12, 2016; 5(3): 97-124
Published online Aug 12, 2016. doi: 10.5501/wjv.v5.i3.97
Published online Aug 12, 2016. doi: 10.5501/wjv.v5.i3.97
Table 1 Anti-varicella-zoster virus seroprevalence rates in women in some countries with a temperate climate
Country | Population | Age | Anti-VZV seroprevalence (%) | Ref. |
United Kingdom | Pregnant women | Mean 28 yr | 95.8 | [301] |
United Kingdom | Pregnant women | Mean 28 yr | 94.8 | [308] |
Spain | Women | 19-39 yr | 92.3 | [309] |
Spain | Women | Not reported | 95.3 | [313] |
Holland | Women | Mean 47 yr | 93 | [311] |
Holland | Women | Mean 29 yr | 100 | [312] |
Slovenia | Women of childbearing age | 15-49 yr | 97.2 | [314] |
Croatia | Women (12% pregnant) | Not reported | 84.3 | [315] |
France | Women | Mean 30.4 yr | 98.8 | [316] |
Germany | Pregnant women | Mean 28 yr | 96.7 | [317] |
Finland | Pregnant women | Mean 30 yr | 95 | [318] |
Italy | Women | 15-39 yr | 87.4 | [321] |
Italy | Pregnant women | 15-49 yr | 89.4 | [310] |
- Citation: De Paschale M, Clerici P. Microbiology laboratory and the management of mother-child varicella-zoster virus infection. World J Virol 2016; 5(3): 97-124
- URL: https://www.wjgnet.com/2220-3249/full/v5/i3/97.htm
- DOI: https://dx.doi.org/10.5501/wjv.v5.i3.97